Barclays PLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Barclays PLC

  • $357 Billion
  • Q4 2024

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 04, 2023
SELL
$0.89 - $2.52 $1.42 Million - $4.02 Million
-1,594,176 Reduced 98.68%
21,271 $19,000
Q4 2022

Feb 13, 2023
BUY
$1.02 - $7.48 $1.11 Million - $8.14 Million
1,088,680 Added 206.67%
1,615,447 $1.91 Million
Q3 2022

Nov 03, 2022
SELL
$6.04 - $9.66 $1,745 - $2,791
-289 Reduced 0.05%
526,767 $3.97 Million
Q2 2022

Aug 12, 2022
BUY
$4.99 - $8.96 $109,076 - $195,856
21,859 Added 4.33%
527,056 $3.32 Million
Q1 2022

May 16, 2022
BUY
$3.84 - $9.74 $1.79 Million - $4.54 Million
466,339 Added 1200.11%
505,197 $4.19 Million
Q4 2021

Feb 14, 2022
BUY
$5.12 - $8.19 $131,937 - $211,048
25,769 Added 196.88%
38,858 $202,000
Q3 2021

Nov 09, 2021
BUY
$6.68 - $9.1 $31,943 - $43,516
4,782 Added 57.57%
13,089 $87,000
Q2 2021

Aug 13, 2021
SELL
$7.82 - $9.23 $142,785 - $168,530
-18,259 Reduced 68.73%
8,307 $70,000
Q1 2021

May 13, 2021
SELL
$8.44 - $12.66 $333,869 - $500,804
-39,558 Reduced 59.82%
26,566 $235,000
Q4 2020

Feb 11, 2021
SELL
$7.98 - $12.29 $162,879 - $250,851
-20,411 Reduced 23.59%
66,124 $814,000
Q3 2020

Nov 12, 2020
BUY
$7.96 - $12.42 $251,313 - $392,124
31,572 Added 57.44%
86,535 $704,000
Q2 2020

Aug 12, 2020
BUY
$5.4 - $13.37 $200,226 - $495,746
37,079 Added 207.33%
54,963 $527,000
Q1 2020

May 13, 2020
SELL
$4.91 - $14.7 $36,019 - $107,839
-7,336 Reduced 29.09%
17,884 $123,000
Q4 2019

Feb 10, 2020
BUY
$9.77 - $15.66 $110,264 - $176,738
11,286 Added 81.0%
25,220 $375,000
Q3 2019

Nov 14, 2019
SELL
$9.59 - $12.0 $35,214 - $44,064
-3,672 Reduced 20.86%
13,934 $142,000
Q2 2019

Aug 14, 2019
SELL
$9.54 - $14.96 $525,568 - $824,161
-55,091 Reduced 75.78%
17,606 $187,000
Q1 2019

May 15, 2019
SELL
$10.31 - $14.38 $143,814 - $200,586
-13,949 Reduced 16.1%
72,697 $1.02 Million
Q4 2018

Feb 14, 2019
BUY
$8.63 - $12.4 $747,720 - $1.07 Million
86,642 Added 2166050.0%
86,646 $881,000
Q1 2018

May 15, 2018
SELL
$8.1 - $16.0 $45,360 - $89,600
-5,600 Reduced 99.93%
4 $0
Q4 2017

Feb 14, 2018
BUY
$10.5 - $14.15 $58,800 - $79,240
5,600 Added 140000.0%
5,604 $78,000
Q3 2017

Nov 14, 2017
BUY
$7.7 - $11.55 $30 - $46
4
4 $0

Others Institutions Holding EIGR

# of Institutions
6
Shares Held
748K
Call Options Held
0
Put Options Held
0
View Full List

About Eiger BioPharmaceuticals, Inc.

EIGR Quotes by TradingView
  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $76.1M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email